|
Expected monthly costs (based on defined daily dose) and cost effectiveness for different PPIs at 2007 price levels [10] |
|||
| Drug |
Defined daily dosea |
Monthly costs (November 2006) |
Cost effectiveness ratio (lower and upper limit)b |
|
|
|||
| Generic omeprazole |
20 mg |
€ 11.30 |
4,907 (2,813 to 6,290) |
| Lansoprazole (Prezal®) |
30 mg |
€ 29.71 |
26,545 (24,327 to 28,051) |
| Omeprazole (Losec®) |
20 mg |
€ 29.85 |
26,709 (24,491 to 28,217) |
| Rabeprazole (Pariet®) |
20 mg |
€ 31.75 |
28,943 (26,711 to 30,463) |
| Pantaprazole (Pantozol®) |
40 mg |
€ 36.41 |
34,420 (32,157 to 35,971) |
| Esomeprazole (Nexium®) |
30 mg |
€ 39.37 |
37,899 (35,617 to 39,470) |
|
aThe daily dosing schedule on which the cost effectiveness ratio is based, may not always reflect the actual dosages prescribed in clinical practice; bcost effectiveness is expressed as costs (€) per serious NSAID ulcer complication prevented: lower and upper limit are the results of the sensitivity analyses. NSAID, non-steroidal anti-inflammatory drug. | |||
Vonkeman et al. Arthritis Research & Therapy 2008 10:R144 doi:10.1186/ar2577 |
|||